---
title: "Equillium IncQ) expected to post a loss of 18 cents a share - Earnings Preview"
description: "Equillium IncQ) is anticipated to report a loss of 18 cents per share for the quarter ending June 30, 2025, with a decline in revenue. The average analyst rating is \"hold,\" with no strong buy or sell "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/251518658.md"
published_at: "2025-08-04T21:52:04.000Z"
---

# Equillium IncQ) expected to post a loss of 18 cents a share - Earnings Preview

> Equillium IncQ) is anticipated to report a loss of 18 cents per share for the quarter ending June 30, 2025, with a decline in revenue. The average analyst rating is "hold," with no strong buy or sell recommendations. The median 12-month price target is $1.00, representing a 43.7% increase from the last closing price of $0.56.

-   Equillium Inc (EQ.OQ) (EQ.O) is expected to show a fall in quarterly revenue when it reports results on August 6 (estimated) for the period ending June 30 2025
-   ​LSEG’s mean analyst estimate for Equillium Inc is for a loss of 18 cents per share.
-   The current average analyst rating on the shares is “hold” and the breakdown of recommendations is no “strong buy” or “buy,” 2 “hold” and no “sell” or “strong sell.”
-   The mean earnings estimate of analysts was unchanged in the last three months. ​
-   Wall Street’s median 12-month price target for Equillium Inc is $1.00, about 43.7% above its last closing price of $0.56 This summary was machine generated August 4 at 21:52 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

### Related Stocks

- [EQ.US - Equillium](https://longbridge.com/en/quote/EQ.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Equillium Conference: EQ504 Targets Ulcerative Colitis Ahead of Mid-Year Phase 1 Start | Equillium (NASDAQ:EQ) executives discussed the development of EQ504, an oral AhR modulator targeting ulcerative colitis, | [Link](https://longbridge.com/en/news/275935079.md) |
| Codeifai Enters AI-Backed Quantum Security Market | Codeifai Ltd :CODEIFAI ENTERS AI-BACKED QUANTUM SECURITY MARKETCOMPLETION OF ACQUISITION OF ANTENNATRANSFER.IOTOTAL CONS | [Link](https://longbridge.com/en/news/276015719.md) |
| Short Interest in Garmin Ltd. (NYSE:GRMN) Increases By 33.2% | Garmin Ltd. (NYSE:GRMN) experienced a 33.2% increase in short interest in January, totaling 3,028,012 shares as of Janua | [Link](https://longbridge.com/en/news/276018254.md) |
| Electrovaya Inc. (NASDAQ:ELVA) Short Interest Update | Electrovaya Inc. (NASDAQ:ELVA) experienced a 24.6% decline in short interest in January, with 334,380 shares short as of | [Link](https://longbridge.com/en/news/276018408.md) |
| Dear Salesforce Stock Fans, Mark Your Calendars for February 25 | Dear Salesforce Stock Fans, Mark Your Calendars for February 25 | [Link](https://longbridge.com/en/news/276007496.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.